SMBC Venture Capital — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Manufacturing technology company; MGP invested in its Series C extension round (2025).
Yushiro Kato(Founder)in
Co-investorsMinerva Growth PartnersAtomicoDCM VenturesGlobal BrainGlobis Capital PartnersMitsubishi UFJ Capital+1 more
PRD Therapeutics is a drug-discovery startup developing first-in-class oral SOAT2-selective inhibitors (PRD compounds derived from pyripyropene A) to regulate lipid metabolism.
BiotechLongevityTokyo, JP
細田 莞爾(代表取締役社長 / President & Co-Founder)供田 洋(社外取締役 / Co-Founder)
Co-investorsJIC Venture Growth InvestmentsJAFCO GroupMizuho Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.